Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

encorafenib

- PMLiVE

Pfizer’s Litfulo significantly improved repigmentation in nonsegmental vitiligo

NSV is a chronic autoimmune disease where the immune system attacks melanin-producing cells, leading to a loss of pigment

- PMLiVE

Smarter science, sharper strategy: Expert insights from ASCO® 2026

As the oncology landscape continues to evolve, life sciences organizations face a growing challenge: how do you communicate increasingly complex science in a way that creates meaningful engagement?

Inizio

- PMLiVE

Pfizer and Valneva’s application for Lyme disease vaccine candidate validated by EMA

There are currently no approved human vaccines for Lyme disease

- PMLiVE

Pfizer announces phase 3 results for nonsegmental vitiligo treatment

Litfulo delivered significant, clinically meaningful improvements for both face and body

- PMLiVE

Pfizer’s Talzenna plus Xtandi gets FDA Priority Review for metastatic prostate cancer

The phase 3 trial showed greater than 50% improvement in radiographic progression-free survival

- PMLiVE

Key takeaways from ASCO® 2026

Following ASCO® 2026, Inizio's experts have shared their perspectives across three thought leadership articles, each exploring a different aspect of what this year's congress revealed for pharmaceutical organisations. Together, they...

Inizio

- PMLiVE

Pfizer announces phase 3 results for potential non-small cell lung cancer treatment

Patients who had received only one prior line of systemic therapy showed a stronger trend for overall survival and progression-free survival

- PMLiVE

Webcast | Smarter science, sharper strategy: Expert perspectives from ASCO® 2026

Key insights from ASCO® 2026, including oncology trends, scientific highlights, and strategies for smarter congress engagement.

Inizio

- PMLiVE

Pfizer and Innovent Biologics agree on deal worth up to $10.5bn

The companies plan to research and develop 12 new cancer treatments

- PMLiVE

Pfizer’s Braftovi combination therapy shows positive results for colorectal cancer

Colorectal cancer is the third most common cancer globally, with approximately 1.8 million people diagnosed in 2022

- PMLiVE

Johnson & Johnson’s Rybrevant shows positive effects in difficult-to-treat colorectal cancer

Colorectal cancer accounts for around 10% of all cancer cases globally, with an increase in diagnoses in younger people

- PMLiVE

Pfizer’s Hympavzi significantly reduces bleeds in haemophilia patients

Over 800,000 people worldwide live with haemophilia

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links